Miracor’s PiCSO Impulse System Receives FDA’s Breakthrough Device Designation for Treatment of Patients with STEMI

 Miracor’s PiCSO Impulse System Receives FDA’s Breakthrough Device Designation for Treatment of Patients with STEMI

Miracor’s PiCSO Impulse System Receives FDA’s Breakthrough Device Designation for Treatment of Patients with STEMI

Shots:

  • Miracor’s PiCSO Impulse System is delivered to the heart’s coronary vessels via minimally invasive procedure in patients with ST-elevated myocardial infarction
  • The PiCSO Impulse System aims to reduce infarct size after STEMI, associated with heart failure hospitalizations and reduced mortality by reducing the onset of HF following myocardial infarction. In July’2019, Miracor reports the onset of PiCSO-AMI-I to evaluate the benefits of PiCSO therapy vs conventional PCI for the treatment of anterior STEMI patients
  • The device’s balloon act by blocking the blood flowing out through the coronary sinus veins resulted in improving perfusion of the infarcted area of the heart

Click here to­ read full press release/ article | Ref: Miracor | Image: Miracor Medical SA

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post